NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Covovax India launch by September; trial for kids soon: SII
    Covovax India launch by September; trial for kids soon: SII
    1/6
    India 2 min read

    Covovax India launch by September; trial for kids soon: SII

    By Siddhant Pandey
    Jun 17, 2021
    12:48 am
    Covovax India launch by September; trial for kids soon: SII
    The trials Novavax’s COVID-19 vaccine, called Covovax, are in the advanced stage.

    The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September. The trials for the vaccine, called Covovax, are in the advanced stage of completion, SII CEO Adar Poonawalla said. Earlier this week, Novavax announced that the vaccine had been found over 90% effective against COVID-19. Here are more details.

    2/6

    Vaccine trial likely to conclude by November

    The trial for the vaccine in India is likely to conclude by November, Poonawalla was quoted as saying by CNBC-TV18. Novavax can apply for a vaccine license before its trial in India on the basis of data available from global trials, Poonawalla said. He said the firm is planning to start clinical trials of Covovax for children in July.

    3/6

    100% protection against moderate, severe infections: Novavax

    Novavax said in a statement on Monday that its vaccine had demonstrated 100% protection against moderate and severe COVID-19 infection and a 90.4% efficacy overall. The study had enrolled 29,960 participants across 119 sites in the US and Mexico to assess the efficacy, safety, and immunogenicity of the vaccine. It demonstrated 93% efficacy against predominant Variants of Concern and Variants of Interest, Novavax said.

    4/6

    Vaccine trial data promising, notes government

    NITI Aayog member Dr. VK Paul told reporters on Tuesday that the SII has been conducting bridging trials for Novavax in India. The data shows that the vaccine is safe and effective, he said, adding that the trials are in the advanced stage of completion. The vaccine will be manufactured by the SII in large quantities, he said.

    5/6

    'Pace of vaccination should see renewed energy from next week'

    Dr. Paul said, "The pace of vaccination should see a renewed energy from next week onwards when we will realign our efforts, state efforts, and effective scale-up at ground level is expected." "Teams both at the Centre and state are working on building new guidelines for high-speed coverage of the vaccination across the country," he added.

    6/6

    Novavax has tiered pricing for lower/middle/upper-income countries

    Novovax recently said that it has a "tiered" pricing scheme for lower-, upper-, and middle-income countries, comparable to most manufacturers. CEO Stanley C Erck said Monday, "Given that we've got a commitment of 1.1 billion doses with COVAX along with our partner Serum Institute (of India), a lot of our first doses are going to go into low- and middle-income countries, as they should."

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Vaccine
    Serum Institute of India
    Adar Poonawalla

    Vaccine

    Calf serum absent in COVAXIN, involved in development, government clarifies Ministry of Health and Family Welfare
    COVID-19: Which Indian states are allowing vaccinated travelers? Travel And Tourism
    Novavax's COVID-19 vaccine is over 90% effective, firm says Coronavirus
    4L COVID-19 vaccine doses to reach states in 3 days Ministry of Health and Family Welfare

    Serum Institute of India

    After Pfizer and Moderna, Serum seeks indemnity over COVID-19 vaccine Pfizer
    Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP Aam Aadmi Party (AAP)
    Government panel recommends 12-16 week gap between Covishield doses Vaccine
    Coronavirus vaccine production to reach 9cr doses in June: Government Government of India

    Adar Poonawalla

    Reports claiming fresh COVID-19 vaccine orders not placed baseless: Government Vaccine
    Getting aggressive calls from powerful people: SII CEO Adar Poonawalla Vaccine
    Covishield price reduced to Rs. 300 for states: Adar Poonawalla Vaccine
    COVID-19 vaccine production hit as US, Europe obstruct raw material Vaccine
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023